Logo image of TBPH

THERAVANCE BIOPHARMA INC (TBPH) Stock Fundamental Analysis

NASDAQ:TBPH - KYG8807B1068 - Common Stock

13.735 USD
-0.11 (-0.76%)
Last: 9/3/2025, 8:00:01 PM
13.735 USD
0 (0%)
After Hours: 9/3/2025, 8:00:01 PM
Fundamental Rating

4

TBPH gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. While TBPH seems to be doing ok healthwise, there are quite some concerns on its profitability. TBPH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

TBPH had negative earnings in the past year.
In the past year TBPH had a positive cash flow from operations.
In the past 5 years TBPH reported 4 times negative net income.
TBPH had a negative operating cash flow in each of the past 5 years.
TBPH Yearly Net Income VS EBIT VS OCF VS FCFTBPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

1.2 Ratios

TBPH has a Return On Assets of 3.06%. This is amongst the best in the industry. TBPH outperforms 85.64% of its industry peers.
With an excellent Return On Equity value of 5.80%, TBPH belongs to the best of the industry, outperforming 85.13% of the companies in the same industry.
Industry RankSector Rank
ROA 3.06%
ROE 5.8%
ROIC N/A
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TBPH Yearly ROA, ROE, ROICTBPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

The Profit Margin of TBPH (16.88%) is better than 90.77% of its industry peers.
The Operating Margin and Gross Margin are not available for TBPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 16.88%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TBPH Yearly Profit, Operating, Gross MarginsTBPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

More info and screens

6

2. Health

2.1 Basic Checks

TBPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TBPH has more shares outstanding
TBPH has less shares outstanding than it did 5 years ago.
TBPH has a worse debt/assets ratio than last year.
TBPH Yearly Shares OutstandingTBPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
TBPH Yearly Total Debt VS Total AssetsTBPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -0.18, we must say that TBPH is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.18, TBPH is in line with its industry, outperforming 50.26% of the companies in the same industry.
The Debt to FCF ratio of TBPH is 0.13, which is an excellent value as it means it would take TBPH, only 0.13 years of fcf income to pay off all of its debts.
TBPH has a Debt to FCF ratio of 0.13. This is amongst the best in the industry. TBPH outperforms 96.41% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that TBPH is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.14, TBPH perfoms like the industry average, outperforming 48.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 0.13
Altman-Z -0.18
ROIC/WACCN/A
WACC10.02%
TBPH Yearly LT Debt VS Equity VS FCFTBPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

TBPH has a Current Ratio of 6.70. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
TBPH has a better Current ratio (6.70) than 75.38% of its industry peers.
A Quick Ratio of 6.70 indicates that TBPH has no problem at all paying its short term obligations.
TBPH has a Quick ratio of 6.70. This is in the better half of the industry: TBPH outperforms 75.38% of its industry peers.
Industry RankSector Rank
Current Ratio 6.7
Quick Ratio 6.7
TBPH Yearly Current Assets VS Current LiabilitesTBPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for TBPH have decreased strongly by -60.47% in the last year.
TBPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 24.48%.
The Revenue has been decreasing by -2.59% on average over the past years.
EPS 1Y (TTM)-60.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92.86%
Revenue 1Y (TTM)24.48%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%83.75%

3.2 Future

Based on estimates for the next years, TBPH will show a very strong growth in Earnings Per Share. The EPS will grow by 27.85% on average per year.
The Revenue is expected to grow by 26.74% on average over the next years. This is a very strong growth
EPS Next Y186.4%
EPS Next 2Y32.82%
EPS Next 3Y32.49%
EPS Next 5Y27.85%
Revenue Next Year79.49%
Revenue Next 2Y28.38%
Revenue Next 3Y19.99%
Revenue Next 5Y26.74%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TBPH Yearly Revenue VS EstimatesTBPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
TBPH Yearly EPS VS EstimatesTBPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 -6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TBPH. In the last year negative earnings were reported.
Also next year TBPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TBPH Price Earnings VS Forward Price EarningsTBPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

99.49% of the companies in the same industry are more expensive than TBPH, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 2.83
EV/EBITDA N/A
TBPH Per share dataTBPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

TBPH's earnings are expected to grow with 32.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.82%
EPS Next 3Y32.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TBPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERAVANCE BIOPHARMA INC

NASDAQ:TBPH (9/3/2025, 8:00:01 PM)

After market: 13.735 0 (0%)

13.735

-0.11 (-0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-10 2025-11-10
Inst Owners91.75%
Inst Owner Change3.2%
Ins Owners4.71%
Ins Owner Change-1.13%
Market Cap691.69M
Analysts80
Price Target18.77 (36.66%)
Short Float %7.4%
Short Ratio11.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-97.38%
Min EPS beat(2)-178.66%
Max EPS beat(2)-16.1%
EPS beat(4)0
Avg EPS beat(4)-62.46%
Min EPS beat(4)-178.66%
Max EPS beat(4)-10.35%
EPS beat(8)2
Avg EPS beat(8)-33.37%
EPS beat(12)3
Avg EPS beat(12)-27.92%
EPS beat(16)4
Avg EPS beat(16)-39.43%
Revenue beat(2)0
Avg Revenue beat(2)-2.01%
Min Revenue beat(2)-2.67%
Max Revenue beat(2)-1.36%
Revenue beat(4)2
Avg Revenue beat(4)2.84%
Min Revenue beat(4)-2.67%
Max Revenue beat(4)7.78%
Revenue beat(8)4
Avg Revenue beat(8)0.44%
Revenue beat(12)5
Avg Revenue beat(12)-3.31%
Revenue beat(16)6
Avg Revenue beat(16)-4.03%
PT rev (1m)6.98%
PT rev (3m)20.66%
EPS NQ rev (1m)19.57%
EPS NQ rev (3m)33%
EPS NY rev (1m)141.08%
EPS NY rev (3m)376.45%
Revenue NQ rev (1m)1.07%
Revenue NQ rev (3m)-4.59%
Revenue NY rev (1m)17.54%
Revenue NY rev (3m)18.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.96
P/FCF 2.83
P/OCF 2.82
P/B 3.08
P/tB 3.08
EV/EBITDA N/A
EPS(TTM)-1.38
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)4.86
FCFY35.39%
OCF(TTM)4.87
OCFY35.42%
SpS1.53
BVpS4.46
TBVpS4.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.06%
ROE 5.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 16.88%
GM N/A
FCFM 317.05%
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 0.13
Debt/EBITDA N/A
Cap/Depr 4.15%
Cap/Sales 0.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 1878.41%
Current Ratio 6.7
Quick Ratio 6.7
Altman-Z -0.18
F-Score9
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)20.39%
Cap/Depr(5y)43.25%
Cap/Sales(3y)1.99%
Cap/Sales(5y)4.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92.86%
EPS Next Y186.4%
EPS Next 2Y32.82%
EPS Next 3Y32.49%
EPS Next 5Y27.85%
Revenue 1Y (TTM)24.48%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%83.75%
Revenue Next Year79.49%
Revenue Next 2Y28.38%
Revenue Next 3Y19.99%
Revenue Next 5Y26.74%
EBIT growth 1Y8.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y242.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y244.25%
OCF growth 3YN/A
OCF growth 5YN/A